UCSD Project 93-418 
7/22/93 
CCTG 705 
Version 1.4 
I. If I am female and capable of child bearing, I will have a pregnancy test prior to 
beginning the study in order to ensure that I am not pregnant. During the study, 
I should make every effort to avoid pregnancy. If I miss a period or think I might 
be pregnant, I will notify the study doctor immediately. If I become pregnant, study 
therapy will be discontinued. If I become pregnant I may discuss with my doctor 
the option of continuing the pregnancy. 
J. No more than 145 ml (5 ounces) of blood will be drawn at any on visit. The total 
amount of blood that will be drawn is 430 ml (15 ounces) during the first 70 days 
of the study. 505 ml (18 ounces) will be drawn during months 3 to 12. 442 ml (15 
ounces) will be drawn during years 2 and 3. 
There is some risk in not taking my anti-HIV medication for the total of 18 days. The 
exact risk of this is unknown, although during this time the HIV in my body could 
increase. 
If I am injured as a result of participation in this research, the University of California will 
provide any medical care I need to treat those injuries-except when they are a 
consequence of research procedures designed to benefit me directly. The University will 
not provide any other form of compensation to me if I am injured. I may call (61 9) 534- 
4520 for more information about this or to report research-related problems. 
There may be no direct benefit to me from this treatment. It is possible that my immune 
system may produce increased levels of CTL against HIV. Information from this study will 
help investigators learn more about the immune defenses to HIV and whether or not we 
can increase these defenses with HIV-IT (V). There is no known alternative to this 
therapy at this time. If my T-cell count is above 500, currently there is no indication for 
therapy. If my T-cell count is less than 500, 1 can receive standard therapy with AZT, ddl, 
ddC, or no therapy at all. 
has explained the study to me and has answered my questions. 
If I have other questions or research related problems I may reach Dr. Richard Haubrich 
at 543-8080. 
Recombinant DNA Research, Volume 18 
[709] 
